Cramer Pamela J. 4

What Happened
Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals (RYTM), was granted two equity awards on February 11, 2026: 11,650 restricted stock units (RSUs) and 17,500 stock option-based awards. Both grants are reported as derivative acquisitions with $0.00 paid at grant (i.e., standard compensation awards rather than open-market purchases).

Key Details

• Transaction date: February 11, 2026; Form 4 filed February 13, 2026 (timely filing).
• Grant amounts: 11,650 RSUs and 17,500 option-based awards; reported price $0.00 (no cash paid).
• Shares owned after transaction: not specified in the filing.
• Footnotes of note:
  • F1/F2: Each RSU represents a contingent right to one share; RSUs vest 25% on each of Feb 1, 2027, 2028, 2029 and 2030; RSUs have no expiration.
  • F3: Options granted Feb 11, 2026 vest in 16 substantially equal installments upon completion of each three full months of service after the grant date (quarterly vesting over four years).
• Transaction type: Award/Grant (code A) — part of executive compensation, not a market buy or sale.

Context

• RSUs convert to shares only as they vest; they are not immediate stock purchases or sales.
• The option awards will vest over time; the filing does not indicate immediate exercise or any subsequent sale.
• These awards are standard compensation practices and should be interpreted as grants tied to continued service, not direct insider buying or selling activity.